Acadia's sweeping hunt for better Nuplazid data bags mixed results for schizophrenia
Five months after their lead drug failed to treat schizophrenia in a Phase III trial, Acadia is touting just-barely significant data that suggest it could help improve a subset of the illness’s symptoms.
The 201 patients given Acadia’s Nuplazid earned a -10.4 on the Negative Symptom Assessment-16 test, against a -8.5 score for the 202 placebo patients. The p-value was 0.043, and the Phase II trial failed on the secondary endpoint: Another psychological assessment called the Personal and Social Performance (PSP).
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 82,000+ biopharma pros reading Endpoints daily — and it's free.